Ability Pharma, a CataloniaBio & HealthTech member, announces the inclusion of the first patients with advanced pancreatic cancer in a Phase IIb clinical trial with ABTL0812.

The study will evaluate the efficacy and safety of ABTL0812 in combination with Folfirinox in 150 patients as first-line therapy. The clinical trial has started simultaneously at the University of Cincinnati Medical Center (USA) and at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Dr Davendra Sohal and Dr Teresa Macarulla are principal investigators, respectively. 

In total, the international study will include sixteen sites: four in the USA, six in Spain, three in France and three in Israel.

“Following the good results obtained in endometrial and lung cancer patients, now we start the development in pancreatic cancer patients which could lead to a faster market approval due to the clear unmet medical need in this indication” says Carles Domènech, co-founder and executive president of Ability.

More information

Photo: Carles Domènech with José Alfón, vice-president of Research and Development at Ability, and Gemma Fierro, vice-president of Regulatory and Clinical Affairs - © Ability Pharma

You may also be interested in:

• Chinese pharma company SciClone joins Ability Pharma shareholders
• Ability closes €2-million round for clinical trials on ABTL0812 to treat pancreatic cancer
• Ability receives €1.6 million from FDA and opens round on Capital Cell